Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis COPD Drug Wil Test The LABA Safety Waters During Advisory Panel Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Given the known risks of long-acting beta-2 agonists, a safety discussion seems likely when the Pulmonary-Allergy Drugs Advisory Committee meets to review Novartis' Arcapta Neohaler (indacaterol maleate).

You may also be interested in...

Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva

The once-daily COPD treatment, already approved in Europe with ho-hum sales, is a lynchpin of Novartis' plan to establish a respiratory franchise.

LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling

Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class

Clinical Trials Or Observational Studies For Asthma? FDA Advisory Panels Can't Agree

Whether randomized controlled clinical trials or observational studies are best for measuring the risks of long acting beta-2 adrenergic agonists remains unresolved after a two-day FDA advisory committee meeting

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts